Heron Therapeutics Inc vs First Trust NASDAQ Clean Edge Green Energy Idx Fd — how do they compare? Heron Therapeutics Inc trades at $0.32 (market cap $61.47M), while First Trust NASDAQ Clean Edge Green Energy Idx Fd trades at $53.21. The key difference: First Trust NASDAQ Clean Edge Green Energy Idx Fd is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| HRTX | QCLN | |
|---|---|---|
Market Cap | $61.47M | — |
Sector | Health | Sector/Thematic |
52-Week High | $1.49 | $68.47 |
52-Week Low | $0.32 | $36.11 |
Enterprise Value | $168.21M | — |
Signals from Pluang's Aura AI — not financial advice
Heron Therapeutics (HRTX) trades at $0.3409, up 3.24% today, but faces bearish technical signals with 18 sell indicators versus 6 buys. The company reported Q2 2026 revenue of $37.7 million but missed earnings expectations with a $0.03 per share loss. Despite strong analyst support (94.7% buy ratings), fundamental challenges persist with negative net income margins and elevated EV/EBITDA of 34.03.
Investment outlook remains cautious due to consistent earnings misses and negative cash flow from operations. The primary opportunity lies in analyst optimism and potential product growth, while risks include ongoing profitability challenges and competitive pressures in the biotechnology sector.
QCLN trades at $53.09, up 2.0% with a bullish technical signal from moving averages. The ETF benefits from clean energy sector momentum driven by data center power demand and global energy security concerns. Recent news highlights clean energy ETF gains amid volatile oil markets, though regulatory challenges and supply chain pressures present headwinds. Key support sits at $51-52 with resistance at $53-55.
The outlook remains positive given structural energy transition trends, but investors face regulatory uncertainty from U.S. permit delays and China trade tensions. Wall Street sentiment leans bullish on clean energy themes, though valuation metrics are unavailable for this ETF. Risks include geopolitical supply chain disruptions and policy shifts affecting renewable project economics.
Trailing returns across standard periods
Latest headlines on both assets
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →QCLN invests in U.S.-listed companies engaged in clean energy technologies. It focuses on solar power, wind, electric vehicles, and energy storage, with major holdings in firms like Tesla, ON Semiconductor, and Rivian.
Read more on QCLN →